Courtesy of Dr. Carlos Fava. One of the characteristics of chronic total occlusion (CTO) is the use of two access routes: femoral and radial. The radial approach is safer, but it has not been thoroughly analyzed in this type of PCI. The study looked at 3709 patients undergoing left main percutaneous coronary intervention (PCI) for<a href="https://solaci.org/en/2019/03/13/cto-in-radial-access-with-similar-results-to-femoral/" title="Read more" >...</a>
We need more evidence to guide us in the management of silent ischemia. Confirmed asymptomatic coronary artery disease is a problem for cardiologists, who lack enough evidence to guide a risk-benefit assessment that justifies revascularization. Revascularizing the outcome of a functional assessment may reduce the rates of death and infarction, or it may just be<a href="https://solaci.org/en/2019/03/12/asymptomatic-coronary-artery-disease-silent-ischemia-a-cardiologists-headache/" title="Read more" >...</a>
According to this new study, in patients with coronary disease, diabetes, and chronic kidney disease who underwent revascularization through angioplasty or surgery, events are similar. This is one of the first studies painting the real picture for the prognosis of patients revascularized in these conditions (diabetes plus chronic kidney disease). At first sight, these<a href="https://solaci.org/en/2019/03/04/revascularization-in-patients-with-multivessel-disease-diabetes-and-kidney-disease/" title="Read more" >...</a>
1- These Were the Most Relevant Article of 2018 in the Field of Coronary Diseases Read the best articles on coronary heart disease from 2018 at solaci website. Read more 2- The 10 Commandments of ESC’s New STEMI Guidelines The authors have given an entertaining account of the most relevant points and differences between<a href="https://solaci.org/en/2019/02/15/the-10-most-read-articles-of-january/" title="Read more" >...</a>
1- What’s New in the European Guidelines on Peripheral Arterial Disease Since the last version of the European guidelines on the diagnosis and treatment of peripheral arterial disease in 2011, there have been many trials and registries that warrant guideline adjustments in many aspects. The first novelty is the teamwork that gave way to these<a href="https://solaci.org/en/2019/02/04/the-most-relevant-articles-of-2018-in-peripheral-vascular-disease/" title="Read more" >...</a>
Patients admitted with transient ST elevation MI and later normalize completely (symptimos disappear before being treated) are those we normally say are “undergoing a non-ST elevation MI”. This is complex, because revascularization time remains nuclear, as is whether to treat them as STEMI or non-STEMI patients. The aim of this study was to determine the<a href="https://solaci.org/en/2019/01/31/optimal-revascularization-time-in-transient-stemi/" title="Read more" >...</a>
The Fourth Universal Definition of Myocardial Infarction is a document developed jointly by the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the American Heart Association (AHA), and the World Heart Federation (WHF). The Fourth Definition was necessary for multiple reasons, including increasingly higher troponin sensitivity. While troponin obviously does not<a href="https://solaci.org/en/2019/01/30/the-ten-commandments-for-the-fourth-universal-definition-of-infarction/" title="Read more" >...</a>
Despite our high hopes for new-generation drug-eluting stents (DES), patients with diabetes still have a different prognosis, both clinical and angiographic, compared with non-diabetic patients. Authors sought to investigate the impact of diabetes on patients who underwent drug-eluting stent implantation in the BIONICS (BioNIR Ridaforolimus Eluting Coronary Stent System in Coronary Stenosis) trial. This<a href="https://solaci.org/en/2019/01/28/outcomes-of-contemporary-des-in-patients-with-diabetes-do-they-render-freedom-obsolete/" title="Read more" >...</a>
1- What Antiplatelet Therapy Should We Use in Patients with Stroke/TIA? Interesting Results for the POINT Trial The New England Journal of Medicine (NEJM) recently published an article about the POINT trial (simultaneously presented at the European Stroke Organisation Conference), a long-awaited randomized clinical trial to assess the efficacy and safety of dual antiplatelet therapy<a href="https://solaci.org/en/2019/01/25/the-most-relevant-articles-of-2018-in-pharmacology-and-clinical-cardiology-part-2/" title="Read more" >...</a>
The new European guidelines on myocardial revascularization were developed by a joint effort of the European Society of Cardiology (ESC) and the European Association of Cardiovascular Surgery (EACTS). These guidelines are intended to support clinical practice with pragmatic recommendations based on currently available evidence and on personal experience, whenever evidence is missing. Both coronary angioplasty<a href="https://solaci.org/en/2019/01/24/the-ten-commandments-of-myocardial-revascularization-according-to-europe/" title="Read more" >...</a>